Cargando…

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance

Patients with diabetes may develop mineralocorticoid receptor (MR) related hypertension due to abnormal activation of MR, thusMR blocker (MRB) is used for the treatment of hypertensionin patients with diabetes. Although theselective MRB esaxerenone (Esax)approved for hypertension, the effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuwabara, Saki, Kameda, Hiraku, Miya, Aika, Nomoto, Hiroshi, Yong Cho, Kyu, Nakamura, Akinobu, Koyanagawa, Naohide, Takeuchi, Jun, Nagai, So, Miyoshi, Arina, Wada, Norio, Taneda, Shinji, Kurihara, Yoshio, Miyoshi, Hideaki, Atsumi, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Diabetes & Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624635/ http://dx.doi.org/10.1210/jendso/bvac150.642

Ejemplares similares

ODP338 Neuromedin B Receptor Antagonist Suppresses ACTH Secretion and Cell Proliferation in Human and Mouse Corticotroph Adenoma
por: Atsumi, Tatsuya, et al.
Publicado: (2022)

ODP279 A Case of Nephrogenic Diabetes Insipidus Diagnosed at an Advanced Age in a Female Patient with an AVPR2 Gene Mutation and Skewed×Inactivation
por: Nakata, Kento, et al.
Publicado: (2022)

ODP332 Maternal Central Diabetes Insipidus Immediately after Delivery, Owing to Vasospasm of the Internal Carotid Artery
por: Yokozeki, Kei, et al.
Publicado: (2022)

ODP285 A Case of Encephalitis and Adrenal Insufficiency in a Patient With Panhypopituitarism After COVID-19 Vaccination
por: Yabe, Ichiro, et al.
Publicado: (2022)

ODP328 Longitudinal Multidisciplinary Approach for Cabergoline-Resistant Aggressive Prolactinoma Complicated by Multiple Endocrine Neoplasia Type 1
por: Furusawa, Sho, et al.
Publicado: (2022)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report
por: Miya, Aika, et al.
Publicado: (2019)

MON-492 A Case of Gitelman’s Syndrome with Hyperphosphatemia That Responded Effectively to Single Oral Administration of Magnesium Oxide
por: Miya, Aika, et al.
Publicado: (2019)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

SAT040 Administration Of A DHCR24 Inhibitor Reduces The Excessive Adrenal Steroidogenesis In db/db Mice Through Effects The Alteration Of Intracellular Cholesterol Metabolism
por: Kamigaki, Risa, et al.
Publicado: (2023)

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
por: Miya, Aika, et al.
Publicado: (2020)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

ODP037 Effects of DHCR24 Inhibitor on Excessive Adrenal Steroidogenesis in db/db mouse
por: Kamigaki, Risa, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
por: Chiba, Koki, et al.
Publicado: (2020)

The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study
por: Handa, Takahisa, et al.
Publicado: (2021)

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring
por: Miya, Aika, et al.
Publicado: (2021)

THU044 The Subcellular Localization Of β-Catenin Is Associated With Tumor Size And The Surgical Remission Rate In Growth Hormone-producing Pituitary Adenomas
por: Kuwabara, Saki, et al.
Publicado: (2023)

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
por: Sekizaki, Tomonori, et al.
Publicado: (2021)

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
por: Nomoto, Hiroshi, et al.
Publicado: (2021)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

SAT-282 Hypothalamic Pituitary Adrenal Axis Hyperactivity in Db/db Mice
por: Kameda, Hiraku, et al.
Publicado: (2020)

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
por: Nakamura, Akinobu, et al.
Publicado: (2020)

Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
por: Miyoshi, Hideaki, et al.
Publicado: (2019)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus
por: Miyoshi, Arina, et al.
Publicado: (2013)

MON-483 Familial Dysalbuminemic Hyperthyroxinemia with False Hypercortisolemia
por: Chiba, Koki, et al.
Publicado: (2020)

Neuromedin B Receptor Antagonist Suppresses Pomc Expression in AtT-20 Cells and Human Corticotroph Adenoma Cells
por: Sekizaki, Tomonori, et al.
Publicado: (2021)

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial
por: Miya, Aika, et al.
Publicado: (2017)

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
por: Cho, Kyu Yong, et al.
Publicado: (2018)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
por: Kitao, Naoyuki, et al.
Publicado: (2017)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia
por: Oba‐Yamamoto, Chiho, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vn0a8l787vstgnpej33h3uav46